EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

The three trials were all testing an experimental once-monthly dosing regimen for Beovu, which is already approved for wet AMD as an injection ... of best corrected visual acuity (BCVA), with ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone ...

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

7. Saxenda – are drugs really the answer to obesity? Novo Nordisk is the market leader in insulin and diabetes injectables, but this year crossed over into the risky field of obesity treatment ...

Choroidal neovascularization (CNV) is one of the most important vision-threatening complications secondary to pathological myopia (PM). In the last 20 years, there have been rapid advances in the ...